The regimen consisting of carboplatin and paclitaxel represents the backbone of ovarian cancer treatment. Here, we reflect on our experience administering the carboplatin/paclitaxel regimen to scores of ovarian cancer patients over the past decade and a half.
A murine study suggests this engineered combination may offer a major advantage over current CAR T-cell–based immunotherapies.
The intratumoral vasculature of high-grade serous ovarian cancer does not appear to undergo significant changes during disease progression.
Recent use of aspirin or NSAIDs is associated with improved ovarian cancer–specific survival.
The approval of PARP inhibitors has caused a paradigm shift in ovarian cancer management and a challenge for clinicians, who must decide how best to use these agents in individualized treatment.
Following diagnosis, only one-third of black women in this retrospective study were referred to genetic counselors—and none actually received counseling.
In women with ovarian cancer, those with early life adversity and anxiety had more dysregulation of cortisol, suggesting they may be at risk for more negative outcomes.
New data suggest adding bevacizumab to chemotherapy may prolong PFS in patients with recurrent ovarian cancer.
Secondary cytoreductive surgery was not associated with improvement in either OS or PFS in patients with platinum-sensitive recurrent ovarian cancer.
The combination of the PARP inhibitor olaparib with the mTORC1/2 inhibitor vistusertib had promising activity across endometrial, ovarian, and triple-negative breast cancers.